Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a proof-of-concept study of OV101 in fragile X syndrome
MOH_2019-07-03_007251Phase 3Not yet recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gaboxadol in Fragile X syndrome (FXS) (3 arms), sponsored by Ovid Therapeutics. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
gaboxadol
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on MOH_2019-07-03_007251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-07-03_007251.